Search by Drug Name or NDC
NDC 00187-3013-30 Mestinon 180 mg/1 Details
Mestinon 180 mg/1
Mestinon is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bausch Health US, LLC. The primary component is PYRIDOSTIGMINE BROMIDE.
MedlinePlus Drug Summary
Pyridostigmine is used to decrease muscle weakness resulting from myasthenia gravis.
Related Packages: 00187-3013-30Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Pyridostigmine
Product Information
| NDC | 00187-3013 |
|---|---|
| Product ID | 0187-3013_f6bf0102-bf43-4f3b-8667-39362bc9cfbb |
| Associated GPIs | 76000050100405 |
| GCN Sequence Number | 004765 |
| GCN Sequence Number Description | pyridostigmine bromide TABLET ER 180 MG ORAL |
| HIC3 | J1B |
| HIC3 Description | CHOLINESTERASE INHIBITORS |
| GCN | 18540 |
| HICL Sequence Number | 001990 |
| HICL Sequence Number Description | PYRIDOSTIGMINE BROMIDE |
| Brand/Generic | Brand |
| Proprietary Name | Mestinon |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | pyridostigmine bromide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 180 |
| Active Ingredient Units | mg/1 |
| Substance Name | PYRIDOSTIGMINE BROMIDE |
| Labeler Name | Bausch Health US, LLC |
| Pharmaceutical Class | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA011665 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00187-3013-30 (00187301330)
| NDC Package Code | 0187-3013-30 |
|---|---|
| Billing NDC | 00187301330 |
| Package | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-3013-30) |
| Marketing Start Date | 1959-01-12 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |